Drug Trial Radar · NCT04976140
Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Dec 15, 2021
Primary completion
Oct 6, 2023
Study completion Oct 6, 2023
Sponsor
- Lead sponsor
- Paean Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the maximum tolerated dose (MTD) based on the safety and tolerability after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis. To explore the efficacy after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis.
Conditions
- Polymyositis
- Dermatomyositis
Interventions
PN-101Biological
PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells. 3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity(DLT)Time frame: 2 weeks after IP administration
- International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)Time frame: 12 weeks after the IP administration
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Soonchunhyang University Seoul Hospital
Seoul, South Korea
Hanyang University Seoul Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.